CD274 and hepatocellular carcinoma: The combination of the immune checkpoint inhibition of programmed death-ligand 1 (PD-L1) atezolizumab and the VEGF neutralizing antibody bevacizumab has become a first-line therapy for patients with advanced HCC (34).